In Brief: Bayer
This article was originally published in The Tan Sheet
Executive Summary
Bayer: NDA for an undisclosed OTC non-steroidal anti-inflammatory drug was filed in the U.S. in "late 1994," according to the firm's recent annual report. The company also reported that clinical trials are continuing with Mycelex as an OTC short-course therapy...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning